Novartis acquires Excellergy for $2 billion

Novartis has acquired Excellergy, an immunology biotech firm, for $2 billion, marking its second multi-billion dollar deal in a week. This strategic acquisition focuses on a next-generation allergy treatment that shows promise for faster and more effective results than current market options. The move underscores Novartis's commitment to expanding its pipeline in immunology and developing innovative therapies. This investment signals confidence in the potential of Excellergy's technology to address unmet medical needs in allergy treatment.